Altogether, these results indicate that both cytoplasmic and mitochondrial ROS play critical role(s) in sorafenib-induced apoptosis of RCC cells; and the cytoprotection of cancer cells through c-Met activation involves the regulation of both forms of ROS. The gene discussed is MET; the disease is renal cell carcinoma.